Published in AIDS Res Hum Retroviruses on August 01, 2010
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform (2004) 72.40
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
HyPhy: hypothesis testing using phylogenies. Bioinformatics (2004) 17.33
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics (1998) 11.25
Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 9.17
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02
Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS (1991) 4.65
Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A (2004) 4.37
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med (2004) 2.68
Convergent evolution: the need to be explicit. Trends Biochem Sci (1994) 2.59
Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1). Mol Biol Evol (1995) 2.51
Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci U S A (1993) 2.49
Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol (1997) 2.11
Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci U S A (1999) 2.02
Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression. Mol Biol Evol (2003) 1.89
Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol (1995) 1.77
Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration. J Virol (2002) 1.75
Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol (2006) 1.68
Evolution of human immunodeficiency virus type 1 nucleotide sequence diversity among close contacts. Proc Natl Acad Sci U S A (1991) 1.58
Humoral immunity to HIV-1: neutralization and beyond. J Intern Med (2007) 1.50
In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother (2006) 1.40
Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J Virol (2003) 1.31
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol (2006) 1.28
Synonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN). Bioinformatics (2002) 1.27
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol (2005) 1.24
Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology (2006) 1.19
Distinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples. Biol Direct (2006) 1.06
Correlation between HIV sequence evolution, specific immune response and clinical outcome in vertically infected infants. AIDS (1997) 1.06
Characterization of the viral population during primary HIV-1 infection. AIDS (1998) 1.05
Molecular tracing of sexual HIV Type 1 transmission in the southwest border of China. AIDS Res Hum Retroviruses (2008) 1.04
Implications of recombination for HIV diversity. Virus Res (2008) 1.04
Genetic variation in mother-child acute seroconverter pairs from Zambia. AIDS (2008) 0.92
Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level. Clin Vaccine Immunol (2007) 0.90
HIV-1-specific CD8+ T cell responses and viral evolution in women and infants. J Immunol (2005) 0.89
Significance of plasma and peripheral blood mononuclear cell derived HIV-1 sequences in establishing epidemiologic linkage between two individuals multiply exposed to HIV-1. Microb Pathog (1999) 0.87
A HIV-1 heterosexual transmission chain in Guangzhou, China: a molecular epidemiological study. Virol J (2009) 0.83
Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort. Retrovirology (2005) 0.83
Patterns of sequence evolution at epitopes for host antibodies and cytotoxic T-lymphocytes in human immunodeficiency virus type 1. Virus Res (2005) 0.83
Conservation of functional domains and limited heterogeneity of HIV-1 reverse transcriptase gene following vertical transmission. Retrovirology (2005) 0.82
HIV-1 variants from a perinatal transmission pair demonstrate similar genetic and replicative properties in tonsillar tissues and peripheral blood mononuclear cells. AIDS Res Hum Retroviruses (2007) 0.77
Why can't the immune system control HIV-1? Defining HIV-1-specific CD4+ T cell immunity in order to develop strategies to enhance viral immunity. Immunol Res (2006) 0.76
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr (2009) 5.48
Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med (2008) 5.13
Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis (2005) 4.96
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA (2008) 3.61
Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54
Men who have sex with men: perceptions about sexual risk, HIV and sexually transmitted disease testing, and provider communication. Sex Transm Dis (2007) 3.51
A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol (2009) 3.26
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One (2012) 2.97
Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS (2005) 2.92
Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking Site. PLoS One (2012) 2.82
A call to action for comprehensive HIV services for men who have sex with men. Lancet (2012) 2.70
High HIV prevalence and risk behaviors in men who have sex with men in Chennai, India. J Acquir Immune Defic Syndr (2004) 2.66
AIDS in America--forgotten but not gone. N Engl J Med (2010) 2.56
Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis (2002) 2.39
Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS One (2013) 2.32
Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr (2006) 2.30
What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med (2012) 2.19
HIV and STD status among MSM and attitudes about Internet partner notification for STD exposure. Sex Transm Dis (2008) 2.18
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis (2009) 2.17
Childhood sexual abuse is highly associated with HIV risk-taking behavior and infection among MSM in the EXPLORE Study. J Acquir Immune Defic Syndr (2009) 2.17
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS (2009) 2.12
When HIV-prevention messages and gender norms clash: the impact of domestic violence on women's HIV risk in slums of Chennai, India. AIDS Behav (2003) 2.12
The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial. J Womens Health (Larchmt) (2003) 2.03
HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav (2014) 2.00
Intimate partner violence is as important as client violence in increasing street-based female sex workers' vulnerability to HIV in India. Int J Drug Policy (2008) 1.97
Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr (2004) 1.97
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Comorbidities among HIV-infected injection drug users in Chennai, India. Indian J Med Res (2008) 1.95
The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis (2005) 1.95
The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities. AIDS Patient Care STDS (2014) 1.94
Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep (2010) 1.90
Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS (2012) 1.86
Unseen and unheard: predictors of sexual risk behavior and HIV infection among men who have sex with men in Chennai, India. AIDS Educ Prev (2009) 1.83
High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr (2008) 1.81
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
Sexual mixing patterns and partner characteristics of black MSM in Massachusetts at increased risk for HIV infection and transmission. J Urban Health (2009) 1.79
Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis (2001) 1.79
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Bisexuality, sexual risk taking, and HIV prevalence among men who have sex with men accessing voluntary counseling and testing services in Mumbai, India. J Acquir Immune Defic Syndr (2010) 1.76
HIV/AIDS and the Black Church: what are the barriers to prevention services? J Natl Med Assoc (2005) 1.74
ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care (2005) 1.73
Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr (2002) 1.71
Health system and personal barriers resulting in decreased utilization of HIV and STD testing services among at-risk black men who have sex with men in Massachusetts. AIDS Patient Care STDS (2009) 1.69
HIV in Indian MSM: reasons for a concentrated epidemic & strategies for prevention. Indian J Med Res (2011) 1.67
Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection. Clin Infect Dis (2013) 1.64
Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr (2008) 1.63
Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world. AIDS (2011) 1.63
Rectal microbicide acceptability: results of a volume escalation trial. Sex Transm Dis (2007) 1.63
Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India. Addiction (2011) 1.62
Risk factors for HIV infection in injection drug users and evidence for onward transmission of HIV to their sexual partners in Chennai, India. J Acquir Immune Defic Syndr (2005) 1.61
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS (2011) 1.60
High HIV burden among people who inject drugs in 15 Indian cities. AIDS (2015) 1.60
High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol (2007) 1.60
Depressive symptoms, utilization of mental health care, substance use and sexual risk among young men who have sex with men in EXPLORE: implications for age-specific interventions. AIDS Behav (2008) 1.59
A survey of MSM HIV prevention outreach workers in Chennai, India. AIDS Educ Prev (2006) 1.58
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57
Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS (2012) 1.56
Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis (2007) 1.56
Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis (2010) 1.55
Prospective associations between HIV-related stigma, transmission risk behaviors, and adverse mental health outcomes in men who have sex with men. Ann Behav Med (2011) 1.55
Emergency department patient acceptance of opt-in, universal, rapid HIV screening. Public Health Rep (2009) 1.54
Contact with HIV prevention programmes & willingness for new interventions among truckers in India. Indian J Med Res (2013) 1.51
Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS (2006) 1.51
Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst (2005) 1.50
Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS (2012) 1.48
HIV/AIDS stigma: reliability and validity of a new measurement instrument in Chennai, India. AIDS Behav (2007) 1.47
HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis (2012) 1.47
Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis (2010) 1.46
GB virus infection: a silent anti-HIV panacea within? Trans R Soc Trop Med Hyg (2008) 1.44
The emerging HIV epidemic among men who have sex with men in Tamil Nadu, India: geographic diffusion and bisexual concurrency. AIDS Behav (2010) 1.43
The efficacy of sirolimus- and paclitaxel-eluting stents: a meta-analysis of randomized controlled trials. Can J Cardiol (2005) 1.42
Clinical profile of HIV in India. Indian J Med Res (2005) 1.41
Resilience as a research framework and as a cornerstone of prevention research for gay and bisexual men: theory and evidence. AIDS Behav (2014) 1.41
Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40
Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother (2006) 1.40
Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt) (2008) 1.40
Perspectives on new recommendations for nonoccupational HIV postexposure prophylaxis. JAMA (2005) 1.39
Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis (2002) 1.38